Category: Company Statements

Statement – Annual Disclosure under ABPI Code, of Payments made by Luye in the Year 2024

Luye Pharma Ltd is committed to transparency in our interactions with Healthcare Professionals (HCPs), with the Healthcare Organisations (HCOs) and Other Relevant Decision Makers (ORDMs), in the United Kingdom.

Luye Pharma Ltd is committed in ensuring transparency of relationships with Healthcare Professionals (HCPs), Healthcare Organisations (HCOs), and other relevant decision makers (ORDMs) by operating within the Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on Disclosure on Transfers of Value.

As part of our commitment to transparency and openness about our activities and to meet the requirements of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, we Luye Pharma Ltd have disclosed all payments of value to members of the Public including to patients and journalists on our company website. Payments or benefits received by HCPs, HCOs, and ORDMs during the 2024 calendar year will be disclosed on a central platform managed by the ABPI and made public in 2025. These payments or benefits to the best of our knowledge are published on the relevant gateway on the ABPI platform and a link to the web page may be accessed here; https://www.abpi.org.uk/reputation/disclosure-uk/.

Luye Pharma Ltd may interact with members of the public for services which may include speaking at meetings, assistance with training, writing articles and/or publications, participating in advisory boards, advising on the design etc of clinical trials and participating in market research where such participation involves remuneration and/or travel. Prior to making any agreements with the members of the public, Luye Pharma Ltd reviews the compliance risks from any engagements. The legal and compliance team at Luye Pharma Ltd, approves the fair market value to be paid for such engagements and the payment is made based on contracts executed between parties.  The written contract specifies the nature of the services to be provided and the payment for those services and, where possible, a breakdown of agreed costs. We apply the on boarding process to assess, screen, validate, manage, and monitor any interactions to ensure that our internal compliance requirements are met. The value of any transfers made is in GBP Stirling (£). Where the payment has been provided by Luye Pharma Ltd or a third-party from outside the UK such payments are provided in the local currency and converted to GBP Stirling (£) using the spot rate during the month of engagement. All payments were reconciled against the contractual agreements, the tracker recordings and the actual payments made.

Donations and Grants to HCOs that support healthcare, including donations and grants to institutions, organisations or associations that are comprised of HCPs and/or that provide healthcare. For financial grants the date of the payment has been recorded as the date the payment was processed by Luye Pharma Ltd.

Luye Pharma Ltd does not disclose payments for any medicines provided on request to HCPs for individual patients which come under ‘Compassionate Use Supply’. Payments made to homecare providers, which Luye Pharma Ltd uses for the delivery of homecare services nationally, have not been included herein for disclosure. Such payments are treated as a fee for service to the vendors who do not fall into the category of HCPs or HCOs and for this this reason, we have taken the view that such payments fall outside the scope for disclosure.

In accordance with the ABPI Code of Practice, to the best of our knowledge we annually disclose all transfers of value made to these individuals and organizations.

Our disclosure includes:

Payments and benefits in kind to HCPs and ORDMs, such as:

• Fees for services and consultancy
• Sponsorship for attendance at meetings
• Travel and accommodation expenses
• Joint working initiatives
• Transfers of value to HCOs, including:
• Donations and grants
• Sponsorship of events/meetings
• Fees for services and consultancy
• Research and development transfers of value

This document summarises the approach taken by Luye Pharma Ltd in calculating the figures provided and considers:

[1] ABPI Code of Practice for the Pharmaceutical Industry 2021. Available from: https://www.abpi.org.uk/reputation/disclosure-uk/

[2] EFPIA Code of practice 2024. Available from: https://www.efpia.eu/relationships-code/the-efpia-code/

[3] PMCPA Disclosure-Methodological Notes points for consideration. Available from: https://www.pmcpa.org.uk/guidance-and-qas/guidance/disclosure-methodological-note-for-annual-disclosure-of-transfers-of-value-to-health-professionals-other-relevant-decision-makers-and-healthcare-organisations/ Legitimate Interest as the Lawful basis for Processing – In the spirit of achieving greater transparency, Luye Pharma Ltd has adopted legitimate Interest as the lawful basis for processing data for disclosure purposes. 

Where an In-Scope Organisation has determined that the measure applies to the procurement, suppliers wishing to bid for that contract are required at the selection stage to submit a Carbon Reduction Plan which details their organisational carbon footprint and confirms their commitment to achieving Net Zero by 2050.

Carbon Reduction Plans are to be completed by the bidding supplier¹ and must meet the reporting requirements set out in supporting guidance, and include the supplier’s current carbon footprint and its commitment to reducing emissions to achieve Net Zero emissions by 2050.

The CRP should be specific to the bidding entity, or, provided certain criteria are met, may cover the bidding entity and its parent organisation. In order to ensure the CRP remains relevant, a Carbon Reduction Plan covering the bidding entity and its parent organisation is only permissible where the detailed requirements of the CRP are met in full, as set out in the Technical Standard² and Guidance³, and all of the following criteria are met:

• The bidding entity is wholly owned by the parent;
• The commitment to achieving net zero by 2050 for UK operations is set out in the CRP for the parent and is supported and adopted by the bidding entity, demonstrated by the inclusion in the CRP of a statement that this will apply to the bidding entity;
• The environmental measures set out are stated to be able to be applied by the bidding entity when performing the relevant contract; and
• The CRP is published on the bidding entity’s website.

Bidding entities must take steps to ensure they have their own CRP as soon as reasonably practicable and should note that the ability to rely on a parent organisation’s Carbon Reduction Plan may only be a temporary measure under this selection criterion. The Carbon Reduction Plan should be updated regularly (at least annually) and published and clearly signposted on the supplier’s UK website. It should be approved by a director (or equivalent senior leadership) within the supplier’s organisation to demonstrate a clear commitment to emissions reduction at the highest level. Suppliers may wish to adopt the key objectives of the Carbon Reduction Plan within their strategic plans.

A template for the Carbon Reduction Plan is set out below. Please complete and publish your Carbon Reduction Plan in accordance with the reporting standard published alongside this PPN.

Supplier name: Luye Pharma Ltd 

Publication date: 05-August-2024

Commitment to achieving Net Zero 

Luye Pharma Ltd is committed to achieving Net Zero emissions by 2050. 

Baseline Emissions Footprint 

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 1 July 2022 – 30 June 2023
Additional Details relating to the Baseline Emissions calculations.
Baseline year emissions: 1 July 2022 – 30 June 2023 was the most recent full year of carbon emissions data.
EMISSIONS	TOTAL (tCO2e)
Scope 1	0
Scope 2	0.37548516
Scope 3  (Included Sources)	378.344
Total Emissions	378.7195

Current Emissions Reporting 

Reporting Year: 1 July 2023 – 30 June 2024
EMISSIONS	TOTAL (tCO2e)
Scope 1	0
Scope 2	0.63911319
Scope 3 (Included Sources)	349.7063
Total Emissions	350.3454

Emissions reduction targets

Luye Pharma Ltd is an expanding business with new products and employees planned which will be a challenge initially in carbon reduction. Luye are committed to achieving Net Zero emissions by 2050 and will work towards limiting carbon emissions during this expansion.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

The following environmental management measures and projects have been completed or implemented prior to the 2022/23 baseline.

Scope 1

Company Facilities: Luye Pharma Ltd are a homebased Company with office space leased on The Surrey Research Park who have prepared a sustainability plan and target of Carbon Net Zero by 2030.

They continue to improve their facilities this includes the list of interventions below;

• The installation of LED lighting
• occupancy/motion sensors
• air source heat pumps (ASHP)
• heat recovery and the removal of fossil fuel heating systems.

These interventions have helped achieve the improved performance of their buildings to 85% now achieving an EPC rating of A-C.

Battery Electric Vehicle (BEV) charging points are available on site.

This data would be reported by The Surrey Research Park and will be excluded from this to avoid double reporting.

Company Vehicles: we do not have any company vehicles, so there are no
emissions from this category included in our emissions data

Scope 2

Purchased electricity, steam, heating and cooling for own use: we don’t purchase
any of the energy needed for our buildings as they are all leased and are covered
by the landlord.

Additional employee has led to increase in home working.

Scope 3

Category 4 and 9 upstream and downstream distribution

Over recent months we have reviewed Supply forecasts with intention to consolidate deliveries of product to pre-wholesaler going forward for current and new product launches.

We have been working with main wholesaler to maintain minimum stock levels and to optimise deliveries from pre wholesaler. 

An ESG statement from our pre-wholesaler is current in progress for future CRP’s. 

Category 5 waste generated in operations 

All outers/shippers/shrink wrap is recycled by Pre-wholesaler. 

Pallets are reused by pre-wholesaler unless damaged, any damaged pallets are returned to their supplier to be recycled. 

Livery: 

Folding box and leaflet: no recycled paper is used 

Label: the pulp for this paper comes from FSC® certified forest management. 

Category 6 business travel – 3 employees + 5 contractors 

Meetings are held via Teams/Zoom with face-to-face meetings kept to a minimum.

Travel is via road and air with some hotel stays mainly within the UK with occasional European.
With the recruitment of a F/T Brand Manager in June23 Luye continues to grow with attendance at a variety of Conferences and meetings with 3rd Party Marketing Company.

Category 7 employee commuting – 3 employees 

Luye Pharma Ltd are a homebased Company with office space leased on The Surrey Research Park. Travel to the office is limited with team meetings approx. 2 – 3 times annually.

Travel is via car.

In the future we hope to implement further measures such as: 

Scope 2: 

Encourage employees /contractors to use 100% renewable electricity energy suppliers. 

Scope 3: 

Category 4 and 9 upstream and downstream distribution: 

Continue to consolidate supply chain to reduce product shipments to pre wholesaler including new launches.

Continue to work with main wholesaler to maintain/increase minimum stock levels and optimise deliveries from pre-wholesaler, extend to other customers.

We will continue to partner with logistics suppliers who prioritise their own environmental impact including GEODIS who have an option to adopt their Air & Sea Sustainable Fuel solution.

Category 5 waste generated in operations: 

Integrate sustainability into product packaging and design. 

Category 6 business travel and Category 7 employee commuting 

Maintain Home Working model, where possible limit business travel and commuting, including continued use of video conferencing, to achieve sustainable long-term reduction of our CO2 emissions. 

Employee learning and behaviour change 

Luye Pharma will continue to raise environmental awareness with all employees/contractors; suppliers and customers, encouraging better energy use and reduced waste. 

Declaration and Sign Off 

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans. 

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard⁴ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting⁵. 

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard⁶. 

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body). 

Signed on behalf of the Supplier: 

Name: Andrew Farrant 

Role: General Manager

Date: 05-Aug-2024 | 06:11:32 PDT

1. Bidding supplier or ‘bidding entity’ means the organisation with whom the contracting authority will enter into a contract if it is successful. ↩︎
2. Technical Standard can be found at:
   https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/991625/PPN_0621_Technical_standard_for_the_Completion_of_Carbon_Reduction_Plans__2_.pdf ↩︎
3. Guidance can be found at:
   https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/991623/Guidance_on_adopting_and_applying_PPN_06_21___Selection_Criteria___3_.pdf ↩︎
4. https://ghgprotocol.org/corporate-standard ↩︎
5. https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting ↩︎
6. https://ghgprotocol.org/standards/scope-3-standard ↩︎